El interés en corto de Cocrystal Pharma da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Cocrystal Pharma. Los datos de interés en corto se actualizan cada dos semanas.

Cocrystal Pharma (NASDAQ:COCP) Bolsa, Informe de interés en corto

Cocrystal Pharma

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Cocrystal Pharma Inc

Egg prices in the U.S. have risen 60% over the past year, due in large part to the bird flu ravaging commercial flocks. Here's a look at why experts see the<a href="https://www.benzinga.com/general/biotech/25/01/43117087/bird-flu-update-first-commercial-case-in-georgia-moderna-receives-590-million-to-develop-vaccine"> prices continuing to climb.</a> 
The Details: The average price for a dozen large, grade-A eggs rose 60% over the past year, reaching $4.15 in December, according <a href="https://data.bls.gov/timeseries/APU0000708111">to data</a> from the Bureau of Labor Statistics. The USDA predicts egg prices <a href="https://www.ers.usda.gov/data-products/food-price-outlook/summary-findings#:~:text=In%202025,%20prices%20for%20all,of%20-2.7%20to%205.5%20percent.%5C">will </a>rise another 45% in 2025 due to a strain of bird flu known as H5N1 that killed 13.2 million commercial egg-laying hens in December.
Read Next: <a href="https://www.benzinga.com/general/travel/25/01/43343648/all-60-passengers-4-crew-members-onboard-american-airlines-jet-feared-dead-after-midair-collision-official-says">64 Killed In American Airlines Midair Collision Near D.C., Worst US Air Disaster Since 2001&nbsp;</a>
On top of the record-high prices, consumers are also facing egg shortages and purchase limits at major retailers like Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) and Albertsons Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>). 
Data from the U.S. Department of Agriculture shows that a record number of more than 20 million egg-laying chickens died in the last quarter due to bird flu.&nbsp;
In an attempt to contain the virus, farmers are compensated for chickens and eggs that are destroyed through a USDA program which said it had paid out $1.25 billion to farmers since the outbreak started in 2022, according to a CBS News <a href="https://www.cbsnews.com/news/egg-industry-chicken-deaths-bird-flu/">report</a>.&nbsp;
In fact, egg producers are reporting record profits during the latest bird flu outbreak. Cal-Maine Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NYSE">CALM</a>), the nation's largest egg producer, reported<a href="https://www.benzinga.com/news/earnings/25/01/42862269/cal-maine-foods-stock-climbs-after-strong-q2-results-eps-beat-revenues-beat"> its most recent </a>quarterly revenue at $954.7 million, well above the $751.49 million consensus estimate.
The company attributed its high revenue in part to restricted supply resulting from bird flu outbreaks. Cal-Maine Foods stock has gained more than 75% over the past six months.&nbsp;
Telsey Advisory Group analyst Sarang Vora initiated coverage this week on Vital Farms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>), a smaller producer specializing in pasture-raised eggs. Vora said he sees the company&#8217;s sales growing at an annual growth rate of 19% to 20% and hitting the $1 billion mark in 2027, versus $600 million in 2024. 
This week, Rose Acre Farms, the second-largest egg producer in the U.S., confirmed its chickens had tested positive for bird flu, likely extending the period of high egg prices and shortages. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43320124/microsoft-shares-slide-after-q2-results-cloud-revenue-misses-expectations-details">Microsoft Shares Slide After Q2 Results, Cloud Revenue Misses Expectations: Details</a>&nbsp;</li>
</ul>
Image: Shutterstock

News

Health Care

General

CALM

COST

VITL

Eggs Prices Soar As Bird Flu Spreads: Why Experts Expect Another 45% Increase In 2025

<a href="https://www.benzinga.com/real-estate/24/12/42368125/i-wonder-how-young-people-today-survive-robert-kiyosaki-says-spending-14-on-an-egg-salad-sandwich-was-hard-to-swallow">Robert Kiyosaki</a>, the author of Rich Dad Poor Dad, has never been shy about making bold predictions. On Jan. 26, he took to X to double down on what <a href="https://www.benzinga.com/personal-finance/24/07/40041316/laugh-all-you-want-robert-kiyosaki-rich-dad-poor-dad-warns-millions-of-401-k-s-and-iras-will-be-">he's been warning about for years</a>: a massive stock market crash. This time, though, he's naming a specific date – February 2025 – as the tipping point for what he calls "the biggest stock market crash in history."
In his post, Kiyosaki referenced his 2013 book, Rich Dad's Prophecy, where he claimed this crash was inevitable. But it's not just doom and gloom from him. Kiyosaki argues that market crashes create opportunities for those prepared, saying everything from cars to houses will "go on sale." He wrote, "Good news because in a crash everything goes on sale. Cars and houses on sale now."
Don't Miss:
<ul>
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-nancy-pelosi">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
Even more interestingly, he predicts that billions will leave traditional investments like stocks and bonds, flowing into assets like Bitcoin, gold and silver. He advises people to "get out of fake and into real," emphasizing that even owning a single Satoshi could be enough to secure wealth in the chaos.
But Kiyosaki isn't alone in predicting trouble.
Goldman Sachs analysts also warn of a significant market correction, estimating a potential 30% drop in 2025. Their concerns stem from high valuations and ongoing economic uncertainty. Economist Harry Dent is on a similar page, pointing to <a href="https://www.benzinga.com/personal-finance/24/11/42236424/1-in-5-dollars-the-government-expends-goes-to-repaying-investors-heres-why-this-spells-trouble-for-trump-and-doge">America's growing private debt</a> as a time bomb waiting to go off. Dent has even said the bubble could burst as early as mid-2025.
Trending: Built on the trusted network of Fortune 500 companies, <a href="https://www.benzinga.com/money/web3-enabler-the-most-boring-blockchain-company-partners-with-salesforce">this blockchain company partners with Salesforce to uproot lengthy and expensive B2B transactions, and you can invest with just $100.</a>
Meanwhile, Jeremy Grantham, a veteran investor known for spotting financial bubbles, is predicting a "cataclysmic decline" in the stock market. He attributes this to overvaluation, demographic shifts like declining population growth, and global challenges such as climate change.
With heavyweights like Kiyosaki, Goldman Sachs, Dent and Grantham all predicting a downturn, the message is clear: prepare now. While the specifics of these warnings differ, they all share a common theme – markets are fragile, and significant challenges are ahead.
For the average investor, this means reassessing your financial strategy. Diversification becomes even more critical in uncertain times. Kiyosaki suggests moving from traditional "fake" assets like stocks and bonds into alternatives like cryptocurrency, gold and silver. While his Bitcoin predictions of "boom, boom, boom" may seem extreme, crypto has historically performed well during periods of economic uncertainty.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
Experts recommend having a clear plan for market volatility. <a href="https://www.benzinga.com/personal-finance/24/08/40531988/you-dont-need-emergency-savings-says-grant-cardone-claims-that-three-months-of-savings-in-case-o">Building emergency savings</a>, paying down debt, and diversifying your investments are key steps to weather a potential storm.
No one can predict the future with absolute certainty, but financial experts' growing chorus of warnings is hard to ignore. Whether or not February 2025 brings the "biggest crash in history," it's a good time to <a href="https://www.benzinga.com/money/are-you-rich">evaluate your financial health</a> and make adjustments if needed. After all, as Kiyosaki often reminds us, in every crash lies an opportunity – if you're prepared for it.
Read Next:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Robert Kiyosaki, 'Rich Dad, Poor Dad,' Warns The Biggest Stock Market Crash Ever Is Coming February – 'Good News Is Everything Goes On Sale'

Outlook
The company anticipates that adjusted earnings per share for the full year 2025 will be in the range of $7.75 to $8.05, which at the mid-point represents EPS growth of 7% excluding the impact of foreign currency translation and a higher tax rate. This range is based on current global economic activity and foreign exchange rates, ongoing soft global industrial production, and mixed demand across the various regions in which we operate. The company expects that annual EPS growth will be weighted toward the second half of 2025 as global industrial demand weakened and the U.S. dollar strengthened in the second half of 2024. Additionally, we expect to realize more than $100 million in annualized share gains in our Industrial Coatings segment beginning in the second half of the year.
Additional information related to 2025 financial projections is posted within the slides and prepared commentary associated with the fourth quarter earnings documents on the Investors section of PPG.com.
The term organic sales as used in this press release is defined as net sales excluding the impact of currency, acquisitions and divestitures.

Guidance

PPG Anticipates Adj EPS For FY25 Will Be In The Range Of $7.75-$8.05 Vs $8.68 Est.

PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) reported quarterly earnings of $1.61 per share which missed the analyst consensus estimate of $1.65 by 2.42 percent. This is a 3.21 percent increase over earnings of $1.56 per share from the same period last year.

Earnings

PPG Indus Q4 Adj EPS $1.61 Misses $1.65 Estimate

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 6.03% on an annualized basis producing an average annual return of 14.45%. Currently, Eli Lilly has a market capitalization of $740.34 billion. 
Buying $100 In LLY: If an investor had bought $100 of LLY stock 20 years ago, it would be worth $1,476.91 today based on a price of $823.23 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738280753_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Wells Fargo analyst Donald Fandetti maintains AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) with a Overweight and lowers the price target from $12 to $11.

Price Target

Analyst Ratings

AGNC

Wells Fargo Maintains Overweight on AGNC Investment, Lowers Price Target to $11

Billionaire Jeff Bezos appears to have a major conflict of interest on his hands with a newspaper he owns trying to get records from another<a href="https://www.benzinga.com/news/21/04/20675447/5-things-you-might-not-know-about-jeff-bezos"> company he founded.</a>
What Happened: While he's <a href="https://www.benzinga.com/news/21/07/21849808/jeff-bezos-is-officially-no-longer-the-amazon-ceo">no longer the CEO</a> of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Bezos remains a shareholder and the executive chairman of the company.
This means that a lawsuit filed by Amazon against the Washington Post, which Bezos owns, now has the billionaire on both sides of the legal fight.
The Washington Post is trying to obtain records related to Amazon's Project Kuiper satellite business, <a href="https://www.hollywoodreporter.com/business/business-news/jeff-bezos-amazon-sues-block-records-requests-washington-post-1236121933/">according </a>to The Hollywood Reporter.
Amazon is fighting back and has sued to block the records request as the e-commerce company states releasing the information could be harmful as it contains trade secrets.
The report says items requested by the news outlet include inspection records, investigation notes and complaints related to visits to the company by the Washington Department of Labor and Industries.
Amazon says the records contain proprietary satellite designs and other information that could give competitors "a competitive edge."
Amazon has not sued the newspaper directly, instead filing a lawsuit against a Washington state agency that agreed to disclose the records. The company is not seeking to block the release of all of the requested records, only a small portion that it believes contains trade secrets.
You may not be a billionaire like Jeff Bezos, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/25/01/43201590/benzinga-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-2">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: The news of the battle by The Washington Post against Amazon comes as the newspaper faces public pushback after <a href="https://www.benzinga.com/general/politics/24/10/41557083/jeff-bezos-ends-washington-posts-36-year-tradition-of-endorsements-leaving-staff-roiled">not endorsing a candidate </a>for president for the first time since 1988.
The decision was said to have been made by Bezos, who bought the newspaper in 2013. The move led to the exit of several newspaper workers and saw around 250,000 subscribers cancel their subscriptions as a result.
The battle between The Washington Post and Amazon and the outcome could become a storyline for Bezos and whether or not billionaires should own news outlets.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/09/41107170/jeff-bezos-used-this-method-to-get-true-opinions-from-employees-amazon-founder-says-youre-the-b">Jeff Bezos Used This Method To Get True Opinions From Employees: Amazon Founder Says &#8216;You&#8217;re The Boss&#8217;</a></li>
</ul>
Photos: Shutterstock

SPACE

Media

AMZN

Bezos Vs. Bezos: Amazon Files Lawsuit Related To Washington Post In Major Conflict Of Interest For Billionaire

Wells Fargo analyst Larry Biegelsen maintains NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) with a Overweight and raises the price target from $13 to $17.

NPCE

Wells Fargo Maintains Overweight on NeuroPace, Raises Price Target to $17

Wells Fargo analyst Ike Boruchow maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Equal-Weight and lowers the price target from $45 to $40.

VSCO

Wells Fargo Maintains Equal-Weight on Victoria's Secret, Lowers Price Target to $40

Wells Fargo analyst Matthew Akers maintains RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) with a Overweight and raises the price target from $151 to $156.

Wells Fargo Maintains Overweight on RTX, Raises Price Target to $156

Wells Fargo analyst Matthew Akers maintains Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) with a Equal-Weight and lowers the price target from $500 to $497.

Wells Fargo Maintains Equal-Weight on Lockheed Martin, Lowers Price Target to $497

Wells Fargo analyst Derek Archila maintains Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) with a Equal-Weight and lowers the price target from $8 to $6.

ZNTL

Wells Fargo Maintains Equal-Weight on Zentalis Pharma, Lowers Price Target to $6

Wells Fargo analyst Zachary Fadem maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Equal-Weight and raises the price target from $145 to $175.

Wells Fargo Maintains Equal-Weight on Brinker International, Raises Price Target to $175

Wells Fargo analyst David Lantz maintains Monro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>) with a Equal-Weight and lowers the price target from $24 to $20.

MNRO

Wells Fargo Maintains Equal-Weight on Monro, Lowers Price Target to $20

Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) has outperformed the market over the past 15 years by 6.96% on an annualized basis producing an average annual return of 19.23%. Currently, Blackstone has a market capitalization of $135.00 billion. 
Buying $1000 In BX: If an investor had bought $1000 of BX stock 15 years ago, it would be worth $13,976.42 today based on a price of $177.82 for BX at the time of writing.
<h3>Blackstone's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738279807_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Wells Fargo analyst Ike Boruchow maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Underweight and raises the price target from $17 to $21.

Wells Fargo Maintains Underweight on VF, Raises Price Target to $21

UBS analyst Alex Kramm maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Neutral and raises the price target from $79 to $89.

NDAQ

UBS Maintains Neutral on Nasdaq, Raises Price Target to $89

UBS analyst Gregg Orrill maintains PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) with a Buy and lowers the price target from $24 to $22.

UBS Maintains Buy on PG&E, Lowers Price Target to $22

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy and lowers the price target from $30 to $27.

TEVA

UBS Maintains Buy on Teva Pharmaceutical Indus, Lowers Price Target to $27

UBS analyst Timothy Arcuri maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Neutral and lowers the price target from $78 to $70.

UBS Maintains Neutral on Western Digital, Lowers Price Target to $70

In a report released today, Ram Selvaraju from H.C. Wainwright maintained a Buy rating on Cocrystal Pharma (COCP – Research Report), with a price t...

Buy Rating Affirmed for Cocrystal Pharma Amid Promising Drug Pipeline and Strong Clinical Results

The latest announcement is out from Cocrystal Pharma ( ($COCP) ). Cocrystal Pharma, Inc. has rewarded its top executives and non-employee directors...

Cocrystal Pharma Boosts Executive and Director Compensation

Cocrystal Pharma ( ($COCP) ) has issued an announcement. Cocrystal Pharma, Inc. is leveraging its innovative, structure-based drug discovery platfo...

Cocrystal Pharma Advances Antiviral Drug Development

Cocrystal Pharma GAAP EPS of -$0.49 beats by $0.08

Cocrystal Pharma (COCP) announces plans to extend enrollment in the Phase 2a human challenge study with its investigational, broad-spectrum, oral i...

Cocrystal Pharma to extend Phase 2a Influenza challenge study

Cocrystal Pharma ( ($COCP) ) has provided an announcement. Cocrystal Pharma announced an extension of enrollment in its Phase 2a human challenge st...

Cocrystal Pharma Extends Enrollment for Influenza Study

Cocrystal stock plunges 40% on influenza drug update

Cocrystal Pharma (COCP) announces safety and tolerability results at dosing up to 800 mg per day for 10 consecutive days from the multiple-ascendin...

Cocrystal Pharma reports Phase 1 safety, tolerability results of CDI-988

The latest update is out from Cocrystal Pharma ( ($COCP) ). Cocrystal Pharma announced positive interim results from a Phase 1 study of its oral pa...

Cocrystal Pharma Reports Positive Phase 1 Study Results

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cocrystal Pharma (COCP – Research Report) today and set a price target of $7.00. R...

Cocrystal Pharma's Promising Drug Developments Garner Buy Rating from Analyst

COCP

Press Releases

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows

Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Events

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts

Cocrystal Pharma's Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins

Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

Comments

Cocrystal Pharma

Interés en corto

Cocrystal Pharma (NASDAQ:COCP) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL